Experimental Approach
We screened out the small-molecule compound NVP-BHG712 targeting CTSK by
molecular docking, and studied its pharmacological effect on bone
resorption function of osteoclasts. To this end, we evaluated bone mass
changes in postmenopausal mice by μCT, ELISA, and H&E staining. In
addition, we also investigated the effects of NVP-BHG712 on osteoclast
differentiation, bone resorption function and expression of osteoclast
differentiation related factors in vitro.